Communiqués Relay Therapeutics, Inc.

Actions

RLAY

US75943R1023

Recherche biotechnologique et médicale

Temps réel estimé 16:57:46 20/08/2026 Varia. 5j. Varia. 1 janv.
19,99 USD -3,62% Graphique intraday de Relay Therapeutics, Inc. +0,13% +135,87%

Communiqués

06/08 Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates GL
30/07 Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 GL
27/05 Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June GL
21/05 Relay Therapeutics Announces Pricing of Public Offering of Common Stock GL
19/05 Relay Therapeutics Announces Proposed Public Offering of Common Stock GL
19/05 Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies GL
06/05 Relay Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) PU
05/05 Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates GL
29/04 Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026 GL
27/04 Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer GL
02/04 Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 GL
16/03 Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 GL
26/02 Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones GL
23/02 Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March GL
19/02 Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 GL
04/02 Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 GL
03/02 Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer GL
03/02 Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer AQ
12/12 Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 GL
06/11 Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates GL
03/11 Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November GL
03/11 Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November AQ
30/10/25 Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 GL
28/08/25 Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September GL
07/08/25 Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates GL
Aucun résultat pour cette recherche